Medscape |
Obinutuzumab Beats Rituximab in CLL
Medscape The new anti-CD20 antibody obinutuzumab (Gazya) performed better than the older product rituximab (Rituxan) when both were added to chemotherapy in previously untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities. North Shore-LIJ Cancer Institute doctors’ editorial publishedEurekAlert (press release) |
North Shore-LIJ Cancer Institute doctors' editorial published – EurekAlert (press release)
|
North Shore-LIJ Cancer Institute doctors’ editorial published
EurekAlert (press release) Researchers compared the benefits of obinutuzumab with that of another antibody rituximab, which also attacks CD20. Both drugs were combined with the chemotherapy drug chlorambucil. They found that subjects receiving obinutuzumab-chlorambucil had … |
The long-awaited call that changed my life – The Border Mail
|
The long-awaited call that changed my life
The Border Mail With that, Ms Coulthard was whisked to Melbourne for the transplant surgery that would literally change her whole life. That was five years ago — up until that day, the Wodonga woman needed oxygen to get through each day living with the rare genetic … |
Introduction: Multidisciplinary Frontline Treatment of mRCC – OncLive
Introduction: Multidisciplinary Frontline Treatment of mRCCOncLiveMost patients with untreated metastatic renal cell carcinoma (mRCC) have already undergone nephrectomy, Rini notes. At this point, the standard frontline treatment is usually the VEGF in…
NIH grantees sharpen understanding of antibodies that may cut risk of HIV … – Science Codex
Daily News & Analysis |
NIH grantees sharpen understanding of antibodies that may cut risk of HIV …
Science Codex What immune response should a vaccine elicit to prevent HIV infection? Two studies published online today bring scientists closer to answering this question by identifying previously unrecognized attributes of antibodies that appear to have reduced the … Past HIV Vaccine Trials Reveal New Path to SuccessNewswise (press release) Past HIV vaccine trials pave way for new treatmentANINEWS |
NIH Grantees Sharpen Understanding of Antibodies That May Cut Risk of HIV … – Infection Control Today
ANINEWSNIH Grantees Sharpen Understanding of Antibodies That May Cut Risk of HIV …Infection Control TodayWhat immune response should a vaccine elicit to prevent HIV infection? Two studies published online today bring scientists closer to answering th…
NIH grantees sharpen understanding of antibodies that may cut risk of HIV … – EurekAlert (press release)
Daily News & Analysis |
NIH grantees sharpen understanding of antibodies that may cut risk of HIV …
EurekAlert (press release) What immune response should a vaccine elicit to prevent HIV infection? Two studies published online today bring scientists closer to answering this question by identifying previously unrecognized attributes of antibodies that appear to have reduced the … Past HIV vaccine trials pave way for new treatmentDaily News & Analysis Lupus may end up saving livesVOXXI |
Factors Behind Low Bone Density in IBD – dailyRx
|
Factors Behind Low Bone Density in IBD
dailyRx These researchers found that both low levels of vitamin D in the blood and the corticosteroids commonly used to treat IBD were associated with low bone density. “Ask your doctor how to reduce bone loss.” Bincy P. Abraham, MD, from the Texas Children’s … |
Teenagers and Chronic Kidney Disease – Washington Informer
Washington Informer |
Teenagers and Chronic Kidney Disease
Washington Informer As a parent, you watch your teenager go through exciting and confusing times – from their involvement in school activities and getting their driver’s license, to choosing which college he or she wants to attend and dealing with loads of peer pressure … |
Biogen Faces Delay in FDA Action Date – Analyst Blog – NASDAQ
The Utah People’s Post |
Biogen Faces Delay in FDA Action Date – Analyst Blog
NASDAQ In addition to Plegridy, Biogen has daclizumab in its MS pipeline. Biogen and partner AbbVie ( ABBV ) are conducting a two-year phase III study (DECIDE) on daclizumab with results due later this year. Biogen is also looking to expand Tysabri’s label … Biogen Idec Inc (NASDAQ:BIIB): A Biotech Pioneer With A Stellar FutureWallStreetPR |